Iovance Biotherapeutics, Inc. IOVA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$79.05M-9.9% | -$71.9M+21.2% | -$91.25M+18.3% | -$111.66M+3.9% | -$116.16M-47.9% | ||
| $2.82M-24.2% | $3.72M+24.7% | $2.99M-12.2% | $3.4M+32.3% | $2.57M-21.5% | ||
| $11.27M-4.6% | $11.82M-0.7% | $11.9M-20.4% | $14.94M-34.8% | $22.92M-26.0% | ||
| -$665K— | $0+100% | -$2.41M-221% | $1.99M+208% | -$1.84M— | ||
| -$28K— | —— | —— | —— | -$44K+99.4% | ||
| -$690K-104% | $15.69M+130% | $6.82M+162% | -$11M-788% | $1.6M-88.2% | ||
| $4.93M+23.2% | $4M+25.7% | $3.18M— | —— | $13.83M-26.9% | ||
| $15.89M+405% | -$5.21M-18.7% | -$4.39M-592% | $893K-56.5% | $2.05M+134% | ||
| -$21.04M-199% | $21.17M+285% | $5.5M— | $0-100% | $2.25M-44.9% | ||
| $1.47M+122% | $661K— | —— | $6.89M+112% | $3.25M-38.9% | ||
| $5.72M-7.9% | $6.2M+7.0% | $5.8M+1.8% | $5.7M+3.7% | $5.5M-48.8% | ||
| $85K+507% | $14K— | —— | $30K-72.7% | $110K— | ||
| $1.88M-30.9% | $2.72M-7.0% | $2.92M+1.6% | $2.88M+0.2% | $2.87M-9.3% | ||
| -$2.03M+30.1% | -$2.9M-20.3% | -$2.41M+2.7% | -$2.48M+20.4% | -$3.11M+14.7% | ||
| -$72.07M-37.1% | -$52.57M+33.2% | -$78.7M-16.7% | -$67.45M+35.0% | -$103.69M-41.5% | ||
| $6.61M-29.1% | $9.32M-14.1% | $10.84M+45.3% | $7.46M+20.1% | $6.21M+49.0% | ||
| $56M-6.5% | $59.91M-35.0% | $92.14M+34.1% | $68.7M-29.8% | $97.92M+11.1% | ||
| $74M+5.7% | $70M-41.7% | $120M+33.3% | $90M-25.0% | $120M+3.4% | ||
| $11.39M+1,370% | $775K-95.4% | $17.01M+22.9% | $13.84M-12.8% | $15.87M— | ||
| $98.51M+76.6% | $55.78M-37.0% | $88.52M+578% | $13.07M-91.2% | $148.94M— | ||
| $4.18M+839% | $445K-4.5% | $466K-7.5% | $504K-91.1% | $5.64M+541% | ||
| $94.34M+67.9% | $56.17M-36.2% | $88.06M+566% | $13.23M-90.8% | $143.32M+6,107% | ||
| -$213K-137% | $577K— | —— | $739K+45.5% | $508K+143% | ||
| $33.44M+574% | $4.96M-80.7% | $25.69M— | —— | $56M+215% | ||
| $1.12M-16.5% | $1.34M-21.6% | $1.71M-14.6% | $2M-6.7% | $2.15M-22.6% | ||
| $5.72M-7.9% | $6.2M+7.0% | $5.8M+1.8% | $5.7M+3.7% | $5.5M-48.8% | ||
| -$434K-216% | $373K+261% | -$232K-249% | $156K+364% | -$59K— | ||
| -$28K— | —— | —— | —— | -$44K— | ||
| —— | —— | —— | —— | —— | ||
| -$2.03M+30.1% | -$2.9M-20.3% | -$2.41M+2.7% | -$2.48M+20.4% | -$3.11M+14.7% | ||
| $1.47M+122% | $661K— | —— | $6.89M+112% | $3.25M-38.9% | ||
| -$506K-114% | $3.7M+166% | $1.39M-83.3% | $8.32M+138,717% | -$6K— | ||
| $1.88M-30.9% | $2.72M-7.0% | $2.92M+1.6% | $2.88M+0.2% | $2.87M-9.3% | ||
| $74M+5.7% | $70M-41.7% | $120M+33.3% | $90M-25.0% | $120M+3.4% | ||
| -$5.89M— | —— | —— | -$6.79M-4.6% | -$6.49M-136% | ||
| —— | —— | —— | —— | $1K— | ||
| -$2.03M+30.1% | -$2.9M-20.3% | -$2.41M+2.7% | -$2.48M+20.4% | -$3.11M+14.7% | ||
| $359K— | —— | $1.74M-9.9% | $1.93M+235% | -$1.43M— | ||
| $85K+507% | $14K— | —— | $30K-72.7% | $110K— | ||
| -$78.68M-27.1% | -$61.89M+30.9% | -$89.55M-19.5% | -$74.91M+31.8% | -$109.91M-41.9% | ||
| -$78.68M-27.1% | -$61.89M+30.9% | -$89.55M-19.5% | -$74.91M+31.8% | -$109.91M-41.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Iovance Biotherapeutics, Inc. generate?
- Iovance Biotherapeutics, Inc. (IOVA) generated -$270.8M in operating cash flow over the trailing twelve months.
- What is Iovance Biotherapeutics, Inc.'s free cash flow?
- After $34.2M of capital expenditures, Iovance Biotherapeutics, Inc.'s free cash flow was -$305.0M over the trailing twelve months, up 12.2% year over year.
- Where does Iovance Biotherapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
